Corey J. Langer, M.D.
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-138
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-138
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
Fax: 215-615-5122
Lab: CP 215-806-6152
Education:
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent linkB.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Description of Research Expertise
Maturing role of immunotherapy in advanced NSCLC.Role of targeted agents in oncogene-driven NSCLC
New strategies in SCLC
Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
Underserved populations, including older patients and those with compromised performance status.
Novel therapeutic venues in thoracic and head and neck cancer
Description of Clinical Expertise
Thoracic Medical Oncology with focus on NSCLC, SCLC, and MesotheliomaSelected Publications
Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer March 2026.Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT.: Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911. Int J Radiat Oncol Biol Phys 124: 50-60, Jul 2025.
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S.: Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer Jun 2025.
Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6: 100851, May 2025.
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME.: Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer 203, May 2025.
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clin Lung Cancer 26(2): 158-163.e2, March 2025.
Stalker M, Walker SL, Lebow E, Pai EL, Watts A, Hwang WT, Banihashemi A, Anderson E, Roshkovan L, Katz SI, Litzky L, Haas AR, Singhal S, Langer CJ, Cengel K, Marmarelis ME.: Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy. JTO Clin Res Rep 6: 100823, Mar 2025.
Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L.: Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC. Clin Lung Cancer 26(2): 124-130.e1, March 2025.
Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ; LUNAR study investigators.: The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study. Lung Cancer 2025.